Immunization Response Varies With Intensity of Acute Lymphoblastic Leukemia Therapy

Ridgway, Derry; Wolff, Lawrence J.; Deforest, Adamadla

doi:10.1001/archpedi.1991.02160080065022

Cited by 15 publications

(20 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The intensity of ALL treatment can influence immune responses [13,16,18]; most of our patients received ALL treatment in accordance with the least intensive MRC-UKALL regimen, and 17% received treatment in accordance with the most intensive regimen; treatment intensity did not appear to influence immunity to the vaccine antigens studied. There were relatively few children who received the most intensive regimen ( ), so this conclusion must be viewed with caution.…”

Section: Discussionmentioning

confidence: 68%

See 1 more Smart Citation

Revaccination of Children after Completion of Standard Chemotherapy for Acute Leukemia

Patel

Ortín

Cohen

et al. 2007

Clinical Infectious Diseases

102

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 68%

“…Relatively few studies have examined this specifically in patients treated for leukemia. Such studies have generally demonstrated a decrease in protective antibody levels after completion of treatment [12][13][14][15][16][17][18][19]. Some have suggested that this decrease may be similar to that experienced by healthy individuals [20].…”

mentioning

confidence: 99%

Revaccination of Children after Completion of Standard Chemotherapy for Acute Leukemia

Patel

Ortín

Cohen

et al. 2007

Clinical Infectious Diseases

102

View full text Add to dashboard Cite

show abstract

“…First, many studies were excluded from this review as they analyzed patient groups during chemotherapy and/or patient groups with other cancers like other hematological malignancies or solid tumors. [24][25][26][27][28][29][30][31][32][33][34][35][36][37] It was not possible to extract data separately for ALL patients after cessation of chemotherapy from these studies. As a consequence, this review represents homogeneous groups of ALL patients after cessation of chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Of these 29 eligible studies, only eight reports met the inclusion criteria. The remaining 21 studies were excluded for the following reasons: only groups less than 10 patients were included (n ¼ 2), 19,20 no data extraction possible (n ¼ 1), 21 antibodies against vaccine-preventable disease not analyzed (n ¼ 2), 12,22 results of children could not be distracted from that of adults (n ¼ 1), 23 patients studied were still on chemotherapy (n ¼ 8) [24][25][26][27][28][29][30][31] and results not stratified for ALL patients only (n ¼ 7). [32][33][34][35][36][37][38] Importantly no randomized controlled trials were available.…”

Section: Study Selectionmentioning

confidence: 99%

Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review

et al. 2006

View full text Add to dashboard Cite

Intensified chemotherapy regimens resulting in improved survival of children with acute lymphocytic leukemia (ALL) lead to concerns about therapy-induced immune damage reflected by the loss of protection of previous immunizations and the efficacy of (re-)vaccination. The severity of secondary immunodeficiency, however, is not clear and knowledge is based on a limited number of studies. We performed a systematic review on literature concerning vaccination data of children with ALL published since 1980. Eight studies fulfilled the inclusion criteria. Regarding antibody titers after treatment, the number of children who had preserved the defined protection level for antibodies differed widely, ranging from 17 to 98% for diphtheria, 27 to 82% for Bordetella pertussis, 20 to 98% for tetanus, 62 to 100% for poliomyelitis, 35 to 100% for Haemophilus influenzae type B (HiB), 29 to 92% for mumps, 29 to 60% for measles and 72 to 92% for rubella. Most patients however responded to revaccination, demonstrating immunological recovery. Although the designs and results of the included studies varied widely, it can be concluded that cytostatic therapy for ALL in children results in a temporarily reduction of specific antibody levels. Memory is preserved but revaccination may be warranted. This is the first systematic review and the best possible current approximation of chemotherapy-induced immune damage in children after ALL treatment.

show abstract

“…2,3 The role of immunization in children receiving chemotherapy for malignant disease remains controversial. 4 Many studies examining the immune status and vaccination responses against vaccine-preventable diseases in bone marrow transplant patients can be found in the literature, [5][6][7][8][9][10][11][12] and effective immunization strategies have been devised for these patients. However, few studies have examined antibody titer levels or the response to immunization in cancer patients during or after chemotherapy.…”

mentioning

confidence: 99%

Antibody Titers and Immune Response to Diphtheria-Tetanus-Pertussis and Measles-Mumps-Rubella Vaccination in Children Treated for Acute Lymphoblastic Leukemia

Ercan¹,

Soycan²,

Apak³

et al. 2005

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

The objective of this study was to investigate the diphtheria-tetanus-pertussis and/or measles-mumps antibody titers before and after vaccination at various time points of acute lymphoblastic leukemia (ALL) therapy and to suggest an appropriate vaccination approach for ALL patients. The authors studied 37 ALL patients and 14 healthy control subjects, divided into three groups. In group 1 (newly diagnosed patients), baseline anti-diphtheria, anti-tetanus, and anti-pertussis titers were determined. Patients in group 2 (on maintenance chemotherapy) and group 3 (patients not receiving therapy for 3-6 months) were vaccinated with diphtheria-tetanus with or without acellular pertussis; group 3 and control subjects were also given measles-mumps-rubella vaccine. Preimmunization and 1-month postimmunization titers were drawn. Preimmunization anti-diphtheria and anti-tetanus antibody titers between the groups and the controls were statistically similar. The seropositivity rate for anti-measles antibody in group 3 was significantly lower than controls. After vaccination, all of the patients developed protective anti-diphtheria and anti-tetanus antibody titers. The seroconversion rates of group 3 and controls for anti-measles and anti-mumps antibodies were statistically similar. The results showed that patients on maintenance therapy and after cessation of therapy made good antibody responses to diphtheria and tetanus toxoids, but response to measles and mumps vaccines was not as sufficient as toxoid vaccines. Children with ALL can receive the appropriate vaccines during and after maintenance treatment.

show abstract

Immunization Response Varies With Intensity of Acute Lymphoblastic Leukemia Therapy

Cited by 15 publications

References 12 publications

Revaccination of Children after Completion of Standard Chemotherapy for Acute Leukemia

Revaccination of Children after Completion of Standard Chemotherapy for Acute Leukemia

Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review

Antibody Titers and Immune Response to Diphtheria-Tetanus-Pertussis and Measles-Mumps-Rubella Vaccination in Children Treated for Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About